Jo Shorthouse

London

Writer at Freelance

Featured in: Favicon

informa.com (+3) Favicon

medicaldevice-network.com Favicon

chemistanddruggist.co.uk Favicon

citeline.com Favicon

medscape.com Favicon

invivo.citeline.com

Articles

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

1 week ago | insights.citeline.com | Jo Shorthouse

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle AgingWhile big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

1 week ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market StrategistBristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Are Sports Drink Just Colorful Delusions?

1 week ago | medscape.com | Jo Shorthouse

Every gym in America is awash in neon. The rainbow array of sports drinks promises to transform weekend warriors into athletic dynamos. For decades, these beverages have occupied a curious space in American consumer culture, somewhere between medicine and marketing, between science and snake oil. Now comes a study showing sports drinks might improve athletic performance. Sort of.
Behind The Buyout: Dispatches From The Dealmaking Table

1 week ago | insights.citeline.com | Jo Shorthouse

Behind The Buyout: Dispatches From The Dealmaking Table In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

2 weeks ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

2 weeks ago | insights.citeline.com | Jo Shorthouse

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory TherapeuticsA German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.
Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

3 weeks ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following ItKura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.
The 360 Degrees Of European Biotech Financing In 2025

1 month ago | insights.citeline.com | Jo Shorthouse

The 360 Degrees Of European Biotech Financing In 2025Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

1 month ago | insights.citeline.com | Jo Shorthouse

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVieFrom chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach. The FDA said dose optimization may be more important for rare diseases because the small patient populations limit the number of possible clinical trials. (Shutterstock)
From IVF Failure To Fertility Breakthroughs: Freya’s Microbiome Mission

1 month ago | insights.citeline.com | Jo Shorthouse

From IVF Failure To Fertility Breakthroughs: Freya’s Microbiome MissionNamed after the Norse goddess of fertility, Freya Biosciences is mapping the reproductive microbiome with a host of women's health indications as the final destination.